港股异动 | 轩竹生物-B(02575)盘中涨超8% NG-350A临床1b期FORTRESS研究初步结果于2026 AACR公布

智通财经
Apr 23

智通财经APP获悉,轩竹生物-B(02575)盘中涨超8%,截至发稿,涨8.65%,报28.4港元,成交额1.19亿港元。

消息面上,4月20日,轩竹生物-B发布公告,NG-350A临床1b期FORTRESS研究的初步结果于2026年4月20日在2026年美国癌症研究协会年会(2026 AACR)公布。NG-350A为一款用于治疗错配修复功能完整(pMMR)局部晚期直肠癌(LARC)的溶瘤免疫疗法药物,由本集团从Akamis Bio, Inc.(Akamis)授权引进。Akamis为一家临床阶段肿瘤药物公司,致力于提升结直肠癌治疗标准。

临床1b期FORTRESS研究(NCT06459869)为一项开放标签、单臂、多中心临床试验,旨在评估NG-350A联合放化疗(CRT)用于治疗pMMR LARC成人患者,患者须至少具备一项局部或远处复发风险因素,或合并寡转移性疾病。本研究正在进行中,旨在评估NG-350A联合放化疗经12周积极治疗后的抗肿瘤作用,以确定相对于单独放化疗,NG-350A是否可提高pMMR局部晚期直肠癌患者的综合缓解率(定义为达到临床完全缓解(cCR)或接近临床完全缓解(ncCR)的患者比例)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10